Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.

Abstract

BACKGROUND:

Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy.

METHODS:

Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80 mg/m(2). In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60 mg/m(2), was infused on day 8.

RESULTS:

The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days.

CONCLUSIONS:

Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.

• Authors: Yoshihisa Sakaguchi, Akira Kabashima, Keishi Okita, Yasutomo Ojima, Shinji Yamamura, Takashi Nishizaki, Hideya Tashiro, Toshimitsu Matsusaka
• Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (Gastric Cancer) Vol. 8 Issue 2 Pg. 111-6 ( 2005) ISSN: 1436-3291 [Print] Japan
• PMID: 15864718 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Drug Combinations
• Pyridines
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Cisplatin

Topics

• Administration, Oral
• Aged
• Antimetabolites, Antineoplastic (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Drug Combinations
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Oxonic Acid (therapeutic use)
• Patient Compliance
• Pyridines (therapeutic use)
• Stomach Neoplasms (drug therapy, pathology)
• Survival Analysis
• Tegafur (therapeutic use)
• Treatment Outcome